News
-
-
PRESS RELEASE
MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA
MIRA Pharmaceuticals, Inc. selects neuropathic pain as the primary indication for its novel oral ketamine analog, Ketamir-2, targeting neurologic disorders. Pre-IND meeting with FDA anticipated in Nov 2024 -
PRESS RELEASE
Nextech3D.ai Signs LOI to Acquire Designhubz Expanding its 3D & AR Portfolio With Try-On Technology For Wearables
Nextech3D.AI acquires Designhubz's AR try-on technology, enhancing immersive eCommerce experiences and personalization capabilities. CEO excited about the expanded market and strategic positioning -
-
-
PRESS RELEASE
Hardman & Co Research on Shield Therapeutics (STX): Focusing on successful execution
Hardman & Co Research provides analysis on Shield Therapeutics (STX) focusing on successful execution. Shield progressing well with sales traction and cost control, aiming for cashflow-break even in 2H'25 -
PRESS RELEASE
Santé Canada approuve (Pr)CABTREO(MC) (phosphate de clindamycine, adapalène et peroxyde de benzoyle), un traitement topique à triple combinaison pour l'acné vulgaire chez les patients âgés de 12 ans et plus
Bausch Health Canada Inc. annonce l'approbation par Santé Canada de PrCABTREO, traitement topique à triple combinaison pour l'acné vulgaire. Disponible Q4 2024 -
PRESS RELEASE
Health Canada Approves (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Triple-Combination Topical Treatment for Acne Vulgaris in Patients 12 Years of Age and Older
Bausch Health, Canada, part of Bausch Health Companies, receives Health Canada approval for new acne treatment CABTREO, a triple-combination topical gel. Dermatology breakthrough for Canadians -
-
